The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
REVANCE THERAPEUTICS, INC. COM 761330109 13,380 848,987 SH   DFND 2, 3, 4 0 0 848,987
REVANCE THERAPEUTICS, INC. COM 761330109 11,181 709,439 SH   DFND 3, 4 0 0 709,439
MYOVANT SCIENCES LTD. COM G637AM102 25,064 1,050,000 SH   DFND 2, 3, 4 0 0 1,050,000
MYOVANT SCIENCES LTD. COM G637AM102 57,876 2,424,645 SH   DFND   0 0 2,424,645